KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Change in Receivables (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Change in Receivables data on record, last reported at -$27.6 million in Q4 2025.

  • For Q4 2025, Change in Receivables fell 734.27% year-over-year to -$27.6 million; the TTM value through Dec 2025 reached -$35.7 million, down 65.36%, while the annual FY2025 figure was -$35.7 million, 65.36% down from the prior year.
  • Change in Receivables reached -$27.6 million in Q4 2025 per CRL's latest filing, down from -$26.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $59.7 million in Q2 2022 and bottomed at -$27.6 million in Q4 2025.
  • Average Change in Receivables over 5 years is $7.7 million, with a median of $3.8 million recorded in 2021.
  • Peak YoY movement for Change in Receivables: skyrocketed 1135.05% in 2022, then crashed 734.27% in 2025.
  • A 5-year view of Change in Receivables shows it stood at -$9.0 million in 2021, then crashed by 163.41% to -$23.6 million in 2022, then decreased by 8.68% to -$25.6 million in 2023, then soared by 87.09% to -$3.3 million in 2024, then plummeted by 734.27% to -$27.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$27.6 million in Q4 2025, -$26.6 million in Q3 2025, and -$10.9 million in Q2 2025.